Market Access and Pricing

What does the legislation mean for patient access leaders, pharma brand managers, and patient service owners? Industry experts weigh in.

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

Balancing innovation focus with optimized decision-making.

Investigators evaluate differences in end-of-life care between Medicare beneficiaries in Medicare Advantage vs. traditional Medicare.

How teamwork among safety-net healthcare providers and pharma can make the difference.

An economic evaluation study assesses these costs by therapeutic class, while identifying trends in pharma R&D intensity over time.

A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.

The impact of income-based price controls in healthcare.

An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.

The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.

A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures.

A difference-in-differences analysis explores the correlation between direct-acting antiviral prescriptions for hepatitis C virus and the softening of state-level limitations.

Although AI has simplified various market access processes, this technology does also present its share of barriers, so what can be done to find a happy medium?

The two company’s will provide consumers with a platform where they can compare drug prices.

Patients should not have to wait to access the medication they need.

Qualitative study breaks down challenges and priorities of the Medicare Shared Savings Program, as noted by affordable care organizations.

Fighting for patient affordability doesn’t necessarily require a scapegoat.

Exploring how current and future legislation may impact the role of pharmacy benefit managers (PBMs).

A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

A USC study discovers that an increasing share of both generic and brand-name meds are being excluded from approval.

An MDVIP study reports that 61% of people feel hassled by the current structure.

A cohort study explores the association of Medicare Advantage enrollment with post-acute care use, along with patient outcomes among retired state employees.

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

A cohort study investigates how a change in clinical guidelines, an expanded label, and reduction in drug prices can impact the use of PCSK9 inhibitors as a treatment for atherosclerotic cardiovascular disease.

A trial set out to determine whether empagliflozin can help prevent hospitalizations and extend life for patients with heart failure, while not hurting the US payers’ pockets.

The lack of transparency in the pharmaceutical industry further exacerbates the challenges faced by consumers.

Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.

Analysis explores where drug prices are derived from, and whether a holistic societal approach can help determine these products’ true value.

Cohort study explores value-based insurance designs, while also determining how one’s place of residency can potentially play a role.